Sahajanand Medical Technologies (SMT) has launched its Hydra Transcatheter Aortic Valve Implantation (TAVI) system in Hungary, achieving promising initial results at the Szegedi Tudományegyetem Szent-György Albert Klinikai Központ. The procedures were conducted under the leadership of Dr Ruzsa Zoltán and Dr Szücsborús Tamás, marking a step forward in minimally invasive treatments for aortic stenosis.
The Hydra TAVI system is designed to meet critical clinical needs by offering precise implantation and simplified coronary access. Its adaptable design aims to enable safe and efficient aortic valve replacement procedures while supporting improved patient outcomes in cardiac care.
“With successful launch of Hydra in Hungary, SMT has further expanded it global TAVI program. We are thrilled with the positive feedback received and it inspires us to keep on innovating and creating positive impact on patient healthcare,”said Gaurav Goel, President of SMT’s Hydra business.
Hydra TAVI is now available in over 20 countries, reflecting SMT’s commitment to global accessibility of high-quality cardiovascular solutions. The company’s efforts align with its mission to advance patient outcomes through minimally invasive cardiac care options worldwide.
“Hydra’s precision in implantation is essential to patient safety and treatment efficacy,” commented Dr Zoltán Ruzsa, MD, PhD. “Our initial experience with Hydra has been very promising, supporting our goal to deliver advanced, effective care.”
Dr Szücsborús Tamás added, “Hydra TAVI aligns perfectly with our objectives to provide patients with innovative and accessible solutions for aortic valve disease.”